Article
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
The Journal of antimicrobial chemotherapy - 1 Aug 2018
Lambert-Niclot S, Grude M, Chaix M L, Charpentier C, Reigadas S, Le Guillou-Guillemette H, Rodallec A, Amiel C, Maillard A, Dufayard J, Mourez T, Mirand A, Guinard J, Montes B, Vallet S, Marcelin A G, Descamps D, Flandre P, Delaugerre C, Morand-Joubert L
Abstract excerpt
Background: Atazanavir is a PI widely used as a third agent in combination ART. We aimed to determine the prevalence and the patterns of resistance in PI-naive patients failing on an atazanavir-based regimen. Methods: We analysed patients failing on an atazanavir-containing regimen used as a first line of PI therapy. We compared the sequences of reverse transcriptase and protease before the introduction of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.